Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval

Mar. 31, 2026 at 8:45pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, polished metal banking machinery and gears, conceptually representing the secure, institutional infrastructure of the financial industry.Femasys' financial results and corporate milestones highlight the company's technological innovations and strategic partnerships aimed at making advanced women's healthcare solutions more accessible.Atlanta Today

Femasys Inc., a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provided a corporate update. The company highlighted key achievements, including initiating patient enrollment in the FINALE pivotal clinical trial for FemBloc, advancing toward U.S. approval, and securing regulatory approvals and strategic partnerships to support the commercialization of its product portfolio.

Why it matters

Femasys' innovative solutions, including FemBloc for non-surgical permanent birth control and FemaSeed for first-line infertility treatment, address critical gaps in women's reproductive healthcare. The company's progress in clinical trials, regulatory approvals, and commercial partnerships demonstrates its commitment to expanding access to these advanced, cost-effective technologies and improving women's healthcare options globally.

The details

Femasys achieved several milestones in the fourth quarter of 2025 and the first quarter of 2026, including initiating patient enrollment in the FINALE pivotal clinical trial for FemBloc, advancing toward U.S. approval; appointing Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors; achieving MDSAP certification for FemBloc; receiving AMA CPT Editorial Panel approval for a new Category III CPT code for FemaSeed; entering a strategic distribution partnership with OR Consulting; and establishing a partnership with Refuah Health Center. The company also secured FDA 510(k) clearance for the FemVue Controlled device and completed a $12 million financing to support ongoing clinical and commercial execution.

  • Femasys initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc in the fourth quarter of 2025.
  • Femasys achieved FemBloc permanent birth control system certification under the Medical Device Single Audit Program (MDSAP) in the fourth quarter of 2025.
  • Femasys received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed intratubal insemination (ITI) in the fourth quarter of 2025.
  • Femasys entered a strategic distribution partnership with OR Consulting to support the commercial launch of FemBloc, FemaSeed, and other products in the fourth quarter of 2025.
  • Femasys established a partnership with Refuah Health Center to advance the adoption of FemaSeed as a first-line infertility treatment in the fourth quarter of 2025.

The players

Femasys Inc.

A leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide.

Kenneth D. Eichenbaum, M.D., M.S.E.

A new member of Femasys' Board of Directors, strengthening the company's leadership and strategic oversight.

Got photos? Submit your photos here. ›

What they’re saying

“During the fourth quarter of 2025 and into the first quarter of 2026 we achieved significant clinical, regulatory and commercial milestones for our FemBloc non-surgical permanent birth control and our FemaSeed first-line intratubal insemination product solutions.”

— Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Femasys' progress in clinical trials, regulatory approvals, and commercial partnerships demonstrates its commitment to expanding access to advanced, cost-effective women's healthcare technologies and improving reproductive options globally.